Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

NCT03149848 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT03149848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03149848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
Lead sponsor
ViiV Healthcare
Phase
Phase 1
Overall status
Completed
Start date
June 6, 2017
Completion date
September 7, 2017
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, infection, human immunodeficiency virus